David Hoang
Stock Analyst at Deutsche Bank
(4.80)
# 503
Out of 4,598 analysts
120
Total ratings
66.3%
Success rate
33.7%
Average return
Main Sectors:
Top Industries:
Stocks Rated by David Hoang
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NBIX Neurocrine Biosciences | Rated: Hold | $155 → $190 | $166.23 | +14.30% | 11 | Jul 31, 2026 | |
| KYMR Kymera Therapeutics | Initiated Coverage: Hold | $120 | $100.31 | +19.63% | 1 | Jul 29, 2026 | |
| DNLI Denali Therapeutics | Rated: Buy | $31 → $35 | $23.15 | +51.19% | 10 | Jul 16, 2026 | |
| JAZZ Jazz Pharmaceuticals | Maintained: Buy | $226 → $270 | $251.58 | +7.32% | 6 | Jul 9, 2026 | |
| HRMY Harmony Biosciences Holdings | Maintained: Hold | $30 → $36 | $35.60 | +1.12% | 7 | Jun 30, 2026 | |
| ACAD ACADIA Pharmaceuticals | Maintained: Buy | $29 → $37 | $25.61 | +44.47% | 10 | Jun 29, 2026 | |
| BHVN Biohaven | Rated: Buy | $65 → $20 | $13.37 | +49.59% | 2 | Jun 26, 2026 | |
| SYRE Spyre Therapeutics | Maintained: Buy | $102 → $135 | $94.93 | +42.21% | 4 | Jun 23, 2026 | |
| APGE Apogee Therapeutics | Downgraded: Hold | $118 → $135 | $134.11 | +0.66% | 4 | Jun 23, 2026 | |
| PRAX Praxis Precision Medicines | Maintained: Buy | $420 → $374 | $305.51 | +22.42% | 9 | Jun 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $281 → $280 | $211.04 | +32.68% | 9 | May 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Sell | $12 → $14 | $15.88 | -11.84% | 23 | Mar 26, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $12 | $7.18 | +67.13% | 1 | Mar 26, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $60 → $90 | $62.26 | +44.56% | 9 | Mar 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $52 → $45 | $49.53 | -9.15% | 3 | Nov 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $7 | $2.18 | n/a | 1 | Jul 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $16 | $8.02 | n/a | 3 | Jul 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $16 | $3.00 | n/a | 1 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Hold | $220 | $220.33 | n/a | 1 | Apr 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $80 | $86.01 | n/a | 1 | Apr 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $24 → $3 | $0.1736 | n/a | 2 | Dec 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $19 | $0.6502 | n/a | 1 | Sep 30, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $73 | $312.57 | n/a | 1 | Mar 12, 2020 |
Neurocrine Biosciences
Jul 31, 2026
Rated: Hold
Price Target: $155 → $190
Current: $166.23
Upside: +14.30%
Kymera Therapeutics
Jul 29, 2026
Initiated Coverage: Hold
Price Target: $120
Current: $100.31
Upside: +19.63%
Denali Therapeutics
Jul 16, 2026
Rated: Buy
Price Target: $31 → $35
Current: $23.15
Upside: +51.19%
Jazz Pharmaceuticals
Jul 9, 2026
Maintained: Buy
Price Target: $226 → $270
Current: $251.58
Upside: +7.32%
Harmony Biosciences Holdings
Jun 30, 2026
Maintained: Hold
Price Target: $30 → $36
Current: $35.60
Upside: +1.12%
ACADIA Pharmaceuticals
Jun 29, 2026
Maintained: Buy
Price Target: $29 → $37
Current: $25.61
Upside: +44.47%
Biohaven
Jun 26, 2026
Rated: Buy
Price Target: $65 → $20
Current: $13.37
Upside: +49.59%
Spyre Therapeutics
Jun 23, 2026
Maintained: Buy
Price Target: $102 → $135
Current: $94.93
Upside: +42.21%
Apogee Therapeutics
Jun 23, 2026
Downgraded: Hold
Price Target: $118 → $135
Current: $134.11
Upside: +0.66%
Praxis Precision Medicines
Jun 2, 2026
Maintained: Buy
Price Target: $420 → $374
Current: $305.51
Upside: +22.42%
May 5, 2026
Rated: Buy
Price Target: $281 → $280
Current: $211.04
Upside: +32.68%
Mar 26, 2026
Maintained: Sell
Price Target: $12 → $14
Current: $15.88
Upside: -11.84%
Mar 26, 2026
Initiated Coverage: Buy
Price Target: $12
Current: $7.18
Upside: +67.13%
Mar 10, 2026
Maintained: Buy
Price Target: $60 → $90
Current: $62.26
Upside: +44.56%
Nov 13, 2025
Maintained: Buy
Price Target: $52 → $45
Current: $49.53
Upside: -9.15%
Jul 25, 2024
Initiated Coverage: Buy
Price Target: $7
Current: $2.18
Upside: n/a
Jul 17, 2024
Maintained: Buy
Price Target: $16
Current: $8.02
Upside: n/a
Mar 6, 2024
Maintained: Buy
Price Target: $16
Current: $3.00
Upside: n/a
Apr 26, 2023
Initiated Coverage: Hold
Price Target: $220
Current: $220.33
Upside: n/a
Apr 26, 2023
Initiated Coverage: Buy
Price Target: $80
Current: $86.01
Upside: n/a
Dec 7, 2022
Downgraded: Hold
Price Target: $24 → $3
Current: $0.1736
Upside: n/a
Sep 30, 2020
Maintained: Buy
Price Target: $19
Current: $0.6502
Upside: n/a
Mar 12, 2020
Initiated Coverage: Buy
Price Target: $73
Current: $312.57
Upside: n/a